Medical artificial intelligence (AI) corporations Lunit said on the 24th that it will present 14 research abstracts on AI medical imaging analysis solutions at the "2025 Radiological Society of North America (RSNA 2025)" to be held in Chicago, United States, from the 30th of this month to Dec. 4. Of these, eight were selected for oral presentations, considered major achievements at the conference, leading to assessments that Lunit's AI technological prowess and market influence have once again been confirmed.
The oral presentations will include: ▲ a performance comparison of four commercial AI algorithms for digital breast tomosynthesis (DBT) reading using Dutch breast cancer screening data ▲ a comparison of the triage performance of seven commercial AI-based mammography systems ▲ the impact of AI on radiologists' decision-making and gaze behavior ▲ the effect of transitioning from traditional double reading to AI-integrated single reading ▲ and a comparison of pneumothorax detection AI accuracy based on chest X-rays.
In particular, studies related to breast density and breast cancer risk prediction draw attention. The oral presentations will cover: ▲ a comparison between high-risk estimates using breast density and existing prediction models ▲ the impact of changes in breast density on calibration and accuracy of risk prediction models ▲ and an analysis of the correlation between breast density and pathological prognostic stage based on data from the United Kingdom breast cancer screening program.
The poster presentations will feature various studies, including: ▲ optimization of AI positive findings for early detection of contralateral breast cancer after breast cancer surgery ▲ analysis of breast cancer subtypes that are easily missed in DBT ▲ a performance comparison between biophysics-based models and commercial breast density assessment models ▲ prediction of risk scores for estrogen receptor–positive breast cancer ▲ and prediction of axillary lymph node metastasis and pathological complete response (pCR) after neoadjuvant chemotherapy.
Seo Beom-seok, Lunit chief executive, said, "RSNA 2025 includes a large number of studies that show the changes AI is bringing to real clinical settings, such as breast cancer screening, risk prediction, and lung disease diagnosis," and "We will strengthen networking with overseas partners so that research results lead to business expansion."